Cover art for AbCellera Presents at UBS Biopharma Conference

AbCellera Presents at UBS Biopharma Conference

AbCellera CEO shares antibody tech advances at UBS Global Biopharma Conference 2026.

Nov 17, 2026

3 cards · 30s · tap to begin

From · · 30s

AbCellera Presents at UBS Biopharma Conference

AbCellera CEO shares antibody tech advances at UBS Global Biopharma Conference 2026.

In brief

AbCellera CEO shares antibody tech advances at UBS Global Biopharma Conference 2026. AbCellera's CEO highlights antibody platform progress targeting GPCRs and ion channels at UBS conference. Originally reported by Seekingalpha.

AbCellera CEO

Carl L. Hansen, CEO, President & Chairperson of AbCellera Biologics Inc. (ABCL) presented at UBS Global Biopharma Conference 2026.

Antibody Platform Focus

AbCellera's 14-year platform targets GPCRs, ion channels, and T-cell engagers with best-in-world technology.

Biotech Business Model

Biotech Business Model

Company initially served pharma clients before developing its own therapeutics including covid-19 treatments.

The essence

AbCellera's CEO highlights antibody platform progress targeting GPCRs and ion channels at UBS conference.

Read the original on Seekingalpha

Read the TL;DR — this story on one card.

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on abcellera and related topics.